Benzinga | Aug 5, 2021 04:32PM EDT

Sangamo Therapeutics Q2 EPS $(0.33) Misses $(0.31) Estimate, Sales $27.87M Beat $26.48M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.31) by 6.45 percent. This is a 26.92 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $27.87 million which beat the analyst consensus estimate of $26.48 million by 5.25 percent. This is a 29.31 percent increase over sales of $21.55 million the same period last year.